Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer

Pryor, David I., Porceddu, Sandro V., Burmeister, Bryan H., Guminski, Alex, Thomson, Damien B., Shepherdson, Kristine and Poulsen, Michael (2009) Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiotherapy and Oncology, 90 2: 172-176. doi:10.1016/j.radonc.2008.09.018

Author Pryor, David I.
Porceddu, Sandro V.
Burmeister, Bryan H.
Guminski, Alex
Thomson, Damien B.
Shepherdson, Kristine
Poulsen, Michael
Title Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer
Journal name Radiotherapy and Oncology   Check publisher's open access policy
ISSN 0167-8140
Publication date 2009-02
Sub-type Article (original research)
DOI 10.1016/j.radonc.2008.09.018
Volume 90
Issue 2
Start page 172
End page 176
Total pages 5
Place of publication Ireland, U.K.
Publisher Elsevier
Language eng
Subject 1112 Oncology and Carcinogenesis
Abstract Purpose To report toxicity data from the first 13 consecutive patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC), ineligible for cisplatin, treated with concurrent cetuximab and radiotherapy (RT) at our institution. Materials and methods Data were collected prospectively between August 2007 and May 2008. Planned treatment consisted of a cetuximab loading dose (400 mg/m2) via intravenous infusion 1 week prior and then weekly (250 mg/m2) with 70 Gy in 35 daily fractions over 7 weeks. Results Median age was 68 years (range 52–82 years). The predominant primary sites were hypopharyngeal (5) and oropharyngeal (5). Ineligibility for cisplatin consisted of renal impairment (5), hearing impairment (4) and of other major co-morbidities (4). Of the 13 patients, 10 (77%) had grade 3/4 skin reactions and 10 (77%) grade 3/4 mucositis. Six (46%) patients required admission for management of severe skin reactions and/or mucositis with 4 (31%) requiring a treatment break, median 10 days (9-15days). Only 4 (31%) patients managed to complete the planned 8 cycles of cetuximab. Of the 9 patients with 12-week post-therapy data, 7 (78%) achieved a complete response. Conclusions Our early experience with cetuximab/RT has demonstrated a higher rate of toxicity compared with the recently reported randomised trial, resulting in low treatment compliance and delays in completing RT.
Keyword Cetuximab
Head and neck
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 59 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 71 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 03 Sep 2009, 08:30:48 EST by Mr Andrew Martlew on behalf of Faculty Of Health Sciences